Author Iain Banks has revealed he has gall bladder cancer and has just "several months" to live.
He said: "I have cancer. It started in my gall bladder, has infected both lobes of my liver and probably also my pancreas and some lymph nodes.
"Plus one tumour is massed around a group of major blood vessels in the same volume, effectively ruling out any chance of surgery to remove the tumours either in the short or long term."
A statement on his official website added:
The bottom line, now, I'm afraid, is that as a late stage gall bladder cancer patient, I'm expected to live for 'several months' and it's extremely unlikely I'll live beyond a year. So it looks like my latest novel, The Quarry, will be my last.
As a result, I've withdrawn from all planned public engagements and I've asked my partner Adele if she will do me the honour of becoming my widow (sorry - but we find ghoulish humour helps). By the time this goes out we'll be married and on a short honeymoon.
We intend to spend however much quality time I have left seeing friends and relations and visiting places that have meant a lot to us. Meanwhile my heroic publishers are doing all they can to bring the publication date of my new novel forward by as much as four months, to give me a better chance of being around when it hits the shelves.
There is a possibility that it might be worth undergoing a course of chemotherapy to extend the amount of time available. However that is still something we're balancing the pros and cons of, and anyway it is out of the question until my jaundice has further and significantly, reduced.
Lastly, I'd like to add that from my GP onwards, the professionalism of the medics involved - and the speed with which the resources of the NHS in Scotland have been deployed - has been exemplary, and the standard of care deeply impressive. We're all just sorry the outcome hasn't been more cheerful.
More top news
The social site has been overhauling many of its policies in recent weeks following repeated criticism over how it handles abusive content.
Niraparib is a PARP inhibitor belonging to a new class of drugs that target cancers with defective DNA repair systems.
According to the EU, during the transition period the UK would have to comply with the bloc's trade policy.